Treatment - Page 38 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Posted by on Sep 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...

Read More

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Posted by on Sep 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....

Read More

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Effectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.

Posted by on Sep 12, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...

Read More

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Posted by on Sep 12, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal time interval between chemoradiotherapy (CRT) and surgery and its impact on survival outcomes in patients with locally advanced (LA) non-small-cell lung cancer (NSCLC). The data showed that surgery within 7 weeks after CRT was associated with improved survival outcomes in these patients. Some...

Read More

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Posted by on Sep 12, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...

Read More

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Posted by on Sep 12, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence.  Some background Early-stage...

Read More

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Posted by on Sep 5, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to determine the long-term outcomes and risk factors after allogeneic stem cell transplantation (allo-SCT) for patients with advanced phase chronic myeloid leukemia (CML).  This study concluded that allo-SCT improved the outcomes of these patients, particularly in those with donors younger than 36...

Read More

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Sep 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...

Read More

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Posted by on Sep 5, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...

Read More

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Posted by on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...

Read More

Is closed-loop glucose control an effective treatment for patients with type 2 diabetes with serious kidney disease?

Is closed-loop glucose control an effective treatment for patients with type 2 diabetes with serious kidney disease?

Posted by on Sep 5, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of closed-loop glucose control treatment for patients with type 2 diabetes (T2D) requiring dialysis. It found that compared to standard insulin therapy, closed-loop glucose control led to improved glucose control in these patients.  Some background Closed-loop glucose control is a form of insulin...

Read More